{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:41:09Z","timestamp":1790232069446,"version":"4.1.0"},"reference-count":49,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,8,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The chemokine CCL3\/MIP-1\u03b1 is a risk factor in the outcome of multiple myeloma (MM), particularly in the development of osteolytic bone disease. This chemokine, highly overexpressed by MM cells, can signal mainly through 2 receptors, CCR1 and CCR5, only 1 of which (CCR1) is responsive to CCL3 in human and mouse osteoclast precursors. CCR1 activation leads to the formation of osteolytic lesions and facilitates tumor growth. Here we show that formation of mature osteoclasts is blocked by the highly potent and selective CCR1 antagonist CCX721, an analog of the clinical compound CCX354. We also show that doses of CCX721 selected to completely inhibit CCR1 produce a profound decrease in tumor burden and osteolytic damage in the murine 5TGM1 model of MM bone disease. Similar effects were observed when the antagonist was used prophylactically or therapeutically, with comparable efficacy to that of zoledronic acid. 5TGM1 cells were shown to express minimal levels of CCR1 while secreting high levels of CCL3, suggesting that the therapeutic effects of CCX721 result from CCR1 inhibition on non-MM cells, most likely osteoclasts and osteoclast precursors. These results provide a strong rationale for further development of CCR1 antagonists for the treatment of MM and associated osteolytic bone disease.<\/jats:p>","DOI":"10.1182\/blood-2011-10-384784","type":"journal-article","created":{"date-parts":[[2012,5,23]],"date-time":"2012-05-23T20:50:23Z","timestamp":1337806223000},"page":"1449-1457","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":82,"title":["CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease"],"prefix":"10.1182","volume":"120","author":[{"given":"Daniel J.","family":"Dairaghi","sequence":"first","affiliation":[{"name":"ChemoCentryx Inc, Mountain View, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babatunde O.","family":"Oyajobi","sequence":"additional","affiliation":[{"name":"Department of Cellular and Structural Biology and"},{"name":"Cancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjana","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Cellular and Structural Biology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"McCluskey","sequence":"additional","affiliation":[{"name":"Department of Cellular and Structural Biology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shichang","family":"Miao","sequence":"additional","affiliation":[{"name":"ChemoCentryx Inc, Mountain View, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay P.","family":"Powers","sequence":"additional","affiliation":[{"name":"ChemoCentryx Inc, Mountain View, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa C.","family":"Seitz","sequence":"additional","affiliation":[{"name":"ChemoCentryx Inc, Mountain View, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"ChemoCentryx Inc, Mountain View, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibin","family":"Zeng","sequence":"additional","affiliation":[{"name":"ChemoCentryx Inc, Mountain View, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penglie","family":"Zhang","sequence":"additional","affiliation":[{"name":"ChemoCentryx Inc, Mountain View, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Schall","sequence":"additional","affiliation":[{"name":"ChemoCentryx Inc, Mountain View, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan C.","family":"Jaen","sequence":"additional","affiliation":[{"name":"ChemoCentryx Inc, Mountain View, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2019111809200504200_B1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2141.2010.08141.x","article-title":"Advances in the understanding of myeloma bone disease and tumour growth.","volume":"149","author":"Yaccoby","year":"2010","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111809200504200_B2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2141.1982.tb03936.x","article-title":"Quantitative histology of myeloma-induced bone changes.","volume":"52","author":"Valentin-Opran","year":"1982","journal-title":"Br J Haematol"},{"issue":"10","key":"2019111809200504200_B3","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1182\/blood-2007-05-093294","article-title":"MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.","volume":"110","author":"Vallet","year":"2007","journal-title":"Blood"},{"issue":"8","key":"2019111809200504200_B4","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2003-11-3839","article-title":"Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion.","volume":"104","author":"Abe","year":"2004","journal-title":"Blood"},{"issue":"8","key":"2019111809200504200_B5","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease.","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"issue":"3","key":"2019111809200504200_B6","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1634\/theoncologist.2009-0003","article-title":"Myeloma bone disease: recent advances in biology, diagnosis, and treatment.","volume":"14","author":"Sezer","year":"2009","journal-title":"Oncologist"},{"key":"2019111809200504200_B7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/978-1-4419-9129-4_4","article-title":"MIP-1 alpha and myeloma bone disease.","volume":"118","author":"Roodman","year":"2004","journal-title":"Cancer Treat Res"},{"issue":"9","key":"2019111809200504200_B8","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1517\/14728222.2011.586634","article-title":"CCR1 as a target for multiple myeloma.","volume":"15","author":"Vallet","year":"2011","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"2019111809200504200_B9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1365-2141.2004.04864.x","article-title":"Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma.","volume":"125","author":"Hashimoto","year":"2004","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111809200504200_B10","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1046\/j.1365-2141.2003.04561.x","article-title":"Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma.","volume":"123","author":"Terpos","year":"2003","journal-title":"Br J Haematol"},{"issue":"12","key":"2019111809200504200_B11","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1080\/10428190500175049","article-title":"Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma.","volume":"46","author":"Terpos","year":"2005","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2019111809200504200_B12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1365-2141.2003.04040.x","article-title":"Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM.","volume":"120","author":"Uneda","year":"2003","journal-title":"Br J Haematol"},{"issue":"11","key":"2019111809200504200_B13","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1038\/leu.2009.130","article-title":"Increased expression of macrophage inflammatory protein-1alpha on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma.","volume":"23","author":"Roussou","year":"2009","journal-title":"Leukemia"},{"issue":"10","key":"2019111809200504200_B14","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.exphem.2010.06.012","article-title":"The cytokine\/chemokine pattern in the bone marrow environment of multiple myeloma patients.","volume":"38","author":"Cao","year":"2010","journal-title":"Exp Hematol"},{"issue":"1","key":"2019111809200504200_B15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2002-12-3905","article-title":"Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease.","volume":"102","author":"Oyajobi","year":"2003","journal-title":"Blood"},{"issue":"7","key":"2019111809200504200_B16","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/leu.2011.43","article-title":"A novel role for CCL3 (MIP-1alpha) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function.","volume":"25","author":"Vallet","year":"2011","journal-title":"Leukemia"},{"issue":"9","key":"2019111809200504200_B17","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1182\/blood-2002-08-2383","article-title":"Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells.","volume":"101","author":"Lentzsch","year":"2003","journal-title":"Blood"},{"issue":"7","key":"2019111809200504200_B18","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.ejca.2010.02.026","article-title":"Interleukin-6 in bone metastasis and cancer progression.","volume":"46","author":"Ara","year":"2010","journal-title":"Eur J Cancer"},{"issue":"4","key":"2019111809200504200_B19","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1517\/14712590902845610","article-title":"RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases.","volume":"9","author":"Terpos","year":"2009","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"2019111809200504200_B20","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nri2972","article-title":"Overcoming hurdles in developing successful drugs targeting chemokine receptors.","volume":"11","author":"Schall","year":"2011","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2019111809200504200_B21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1517\/13543770802641346","article-title":"Chemokine receptor antagonists: Part 1.","volume":"19","author":"Pease","year":"2009","journal-title":"Expert Opin Ther Pat"},{"issue":"5","key":"2019111809200504200_B22","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10585-006-9038-6","article-title":"Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model.","volume":"23","author":"Menu","year":"2006","journal-title":"Clin Exp Metastasis"},{"issue":"3","key":"2019111809200504200_B23","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.exphem.2004.11.015","article-title":"MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells.","volume":"33","author":"Oba","year":"2005","journal-title":"Exp Hematol"},{"issue":"6","key":"2019111809200504200_B24","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1182\/blood.V100.6.2195.h81802002195_2195_2202","article-title":"Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma.","volume":"100","author":"Abe","year":"2002","journal-title":"Blood"},{"issue":"5","key":"2019111809200504200_B25","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/clpt.2011.33","article-title":"Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose.","volume":"89","author":"Dairaghi","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"2019111809200504200_B26","first-page":"3000","article-title":"CCR1 blockade by an orally-available CCR1 antagonist reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease [abstract].","volume":"116","author":"Oyajobi","year":"2010","journal-title":"Blood (ASH Annual Meeeting Abstracts)"},{"key":"2019111809200504200_B27","article-title":"Azaindazole compounds and methods of use.","author":"Zhang","year":"2008","journal-title":"United States pat pub US20080058341"},{"key":"2019111809200504200_B28","article-title":"Chemokine receptor 1 antagonist CCX354-C treatment for rheumatoid arthritis [published online ahead of print May 5, 2012].","author":"Tak","journal-title":"Ann Rheum Dis"},{"issue":"21","key":"2019111809200504200_B29","doi-asserted-by":"crossref","first-page":"6895","DOI":"10.1158\/1078-0432.CCR-08-0285","article-title":"Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma.","volume":"14","author":"Murillo","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2019111809200504200_B30","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1158\/1535-7163.MCT-07-0121","article-title":"Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging.","volume":"6","author":"Oyajobi","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"2019111809200504200_B31","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1124\/jpet.110.169714","article-title":"Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease.","volume":"335","author":"Walters","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"2019111809200504200_B32","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1182\/blood.V93.5.1697","article-title":"Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease.","volume":"93","author":"Dallas","year":"1999","journal-title":"Blood"},{"issue":"5","key":"2019111809200504200_B33","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.4049\/jimmunol.176.5.3141","article-title":"The human specific CCR1 antagonist CP-481,715 inhibits cell infiltration and inflammatory responses in human CCR1 transgenic mice.","volume":"176","author":"Gladue","year":"2006","journal-title":"J Immunol"},{"issue":"12","key":"2019111809200504200_B34","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1172\/JCI200113116","article-title":"Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease.","volume":"108","author":"Choi","year":"2001","journal-title":"J Clin Invest"},{"issue":"1","key":"2019111809200504200_B35","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11010-007-9485-7","article-title":"Macrophage inflammatory protein-1alpha (MIP-1alpha) enhances a receptor activator of nuclear factor kappaB ligand (RANKL) expression in mouse bone marrow stromal cells and osteoblasts through MAPK and PI3K\/Akt pathways.","volume":"304","author":"Tsubaki","year":"2007","journal-title":"Mol Cell Biochem"},{"issue":"11","key":"2019111809200504200_B36","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1182\/blood.V97.11.3349","article-title":"Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand.","volume":"97","author":"Han","year":"2001","journal-title":"Blood"},{"issue":"4","key":"2019111809200504200_B37","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/jcb.10319","article-title":"CCL9\/MIP-1gamma and its receptor CCR1 are the major chemokine ligand\/receptor species expressed by osteoclasts.","volume":"87","author":"Lean","year":"2002","journal-title":"J Cell Biochem"},{"issue":"5","key":"2019111809200504200_B38","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1210\/en.2005-0065","article-title":"Functional expression of beta-chemokine receptors in osteoblasts: role of regulated upon activation, normal T cell expressed and secreted (RANTES) in osteoblasts and regulation of its secretion by osteoblasts and osteoclasts.","volume":"146","author":"Yano","year":"2005","journal-title":"Endocrinology"},{"issue":"2","key":"2019111809200504200_B39","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/(SICI)1097-4652(200005)183:2<196::AID-JCP6>3.0.CO;2-8","article-title":"CKbeta-8 [CCL23], a novel CC chemokine, is chemotactic for human osteoclast precursors and is expressed in bone tissues.","volume":"183","author":"Votta","year":"2000","journal-title":"J Cell Physiol"},{"issue":"37","key":"2019111809200504200_B40","doi-asserted-by":"crossref","first-page":"28826","DOI":"10.1074\/jbc.M109.099424","article-title":"Deficiency of chemokine receptor CCR1 causes osteopenia due to impaired functions of osteoclasts and osteoblasts.","volume":"285","author":"Hoshino","year":"2010","journal-title":"J Biol Chem"},{"issue":"10","key":"2019111809200504200_B41","doi-asserted-by":"crossref","first-page":"5698","DOI":"10.1073\/pnas.96.10.5698","article-title":"A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity.","volume":"96","author":"Baba","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2019111809200504200_B42","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S8756-3282(97)00056-2","article-title":"A murine model of human myeloma bone disease.","volume":"20","author":"Garrett","year":"1997","journal-title":"Bone"},{"issue":"7","key":"2019111809200504200_B43","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood-2004-01-0236","article-title":"Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis.","volume":"104","author":"Mori","year":"2004","journal-title":"Blood"},{"issue":"10","key":"2019111809200504200_B44","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood-2005-09-3870","article-title":"Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma.","volume":"107","author":"Goel","year":"2006","journal-title":"Blood"},{"key":"2019111809200504200_B45","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S1040-8428(11)70004-X","article-title":"Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease.","volume":"77","author":"Terpos","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"2019111809200504200_B46","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S1040-8428(11)70005-1","article-title":"Can bisphosphonates improve outcomes in patients with newly diagnosed multiple myeloma?","volume":"77","author":"Morgan","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"2019111809200504200_B47","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities.","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"2019111809200504200_B48","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1158\/0008-5472.CAN-03-1131","article-title":"Cancer and the microenvironment: myeloma-osteoclast interactions as a model.","volume":"64","author":"Yaccoby","year":"2004","journal-title":"Cancer Res"},{"issue":"15","key":"2019111809200504200_B49","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.4155\/fmc.11.144","article-title":"Therapeutic potential of CCR1 antagonists for multiple myeloma.","volume":"3","author":"Karash","year":"2011","journal-title":"Future Med Chem"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/7\/1449\/1499291\/zh803312001449.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/7\/1449\/1499291\/zh803312001449.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T10:23:28Z","timestamp":1574072608000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/7\/1449\/30763\/CCR1-blockade-reduces-tumor-burden-and-osteolysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,16]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,8,16]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-10-384784","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,16]]}}}